Core Insights - The healthcare industry is highly volatile, with company fortunes heavily influenced by product success and clinical trial results, leading to significant stock price fluctuations [1] - A "picks and shovels" investment strategy focusing on essential equipment and services may be more appealing to investors concerned about volatility in the healthcare sector [1] Lab Equipment Sector - Lab equipment stocks are often overlooked, yet some of the largest companies in healthcare are in this subindustry, making them worthy of investor attention [2] - Factors such as shifting subsidies, an aging population, inflation, and the growing role of AI could enhance the appeal of core lab equipment companies in 2026 [2] Thermo Fisher Scientific - Thermo Fisher Scientific, a $182-billion company, has faced a challenging start to 2026, with shares down over 15% year-to-date due to tariffs and foreign exchange volatility impacting margins [3] - Despite recent stock performance, Thermo Fisher reported Q4 2025 revenue of $12.2 billion, a 7% year-over-year increase, surpassing analyst expectations by $250 million, with adjusted earnings per share at $6.57 [4] - Recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor products, may have contributed to this positive momentum [5] Market Trends - Many lab equipment stocks have seen declines in the high-teens this year, but modest sales growth may indicate underlying strengths [7] - These companies may offer a more secure investment approach compared to higher-risk alternatives in the healthcare sector, although challenges such as tariffs and inflation persist [7]